Anti-edematous Effects of Tolvaptan in Experimental Rodent Models

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2011-11-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-011-6355-zPMID 22120096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats

  2009cited by this paper
• Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.

  2008cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

  2007cited by this paper
• Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

  2006cited by this paper
• Sustained aquaretic effect of the V2‐AVP receptor antagonist, RWJ‐351647, in cirrhotic rats with ascites and water retention

  2005cited by this paper
• Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial

  2004cited by this paper
• Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

  2004cited by this paper
• Mechanisms and management of diuretic resistance in congestive heart failure.

  2003cited by this paper
• Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.

  2003cited by this paper
• Mechanisms and management of diuretic resistance in congestive heart failure

  2003cited by this paper
• Vasopressin V2 receptor antagonists.

  2002cited by this paper
• Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.

  2000cited by this paper
• Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

  2000cited by this paper
• 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.

  1999cited by this paper
• OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

  1998cited by this paper
• Potassium Disturbances Associated with the Use of Diuretics

  1997cited by this paper
• Edema and principles of diuretic use.

  1997cited by this paper
• Sodium: Volume Depletion and Hyponatremia

  1997cited by this paper
• Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.

  1994cited by this paper
• Cloning and characterization of the human V3 pituitary vasopressin receptor

  1994cited by this paper
• Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.

  1994cited by this paper
• Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats.

  1994cited by this paper
• Molecular cloning and expression of a rat Via arginine vasopressin receptor

  1992cited by this paper
• Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus

  1992cited by this paper
• Molecular cloning of the receptor for human antidiuretic hormone

  1992cited by this paper
• The vasopressin-sensitive adenylate cyclase in collecting tubules and in thick ascending limb of Henle's loop of human and canine kidney.

  1985cited by this paper
• Sites of hormone action in the mammalian nephron.

  1981cited by this paper
• Adenylate cyclase responsiveness to hormones in various portions of the human nephron.

  1980cited by this paper
• Effect of vasopressin on electrical potential difference and chloride transport in mouse medullary thick ascending limb of Henle's loop.

  1980cited by this paper
• Different hormonal target sites along the mouse and rabbit nephrons.

  1977cited by this paper

• In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan.

  2022cites this paper
• Low-intensity ultrasound attenuates paw edema formation and decreases vascular permeability induced by carrageenan injection in rats

  2020cites this paper
• ARGININE VASOPRESSIN RECEPTOR 2 ACTIVATION PROMOTES MICROVASCULAR PERMEABILITY IN SEPSIS.

  2020cites this paper
• Tolvaptan attenuated brain edema in experimental intracerebral hemorrhage.

  2019cites this paper
• Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.

  2013cites this paper
• Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.

  2013cites this paper
• Tolvaptan Improves Left Ventricular Dysfunction after Myocardial Infarction in Rats

  2012cites this paper
• Experimental model to myositis induction in mice microscopic evaluation

  2012cites this paper
• Tolvaptan for Heart Failure Patients with Volume Overload

  2011cites this paper